Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs State Street SPDR S&P Biotech ETF — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while State Street SPDR S&P Biotech ETF trades at $159.97. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| BIL | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $91.77 | $164.28 |
52-Week Low | $91.27 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL, the SPDR Bloomberg 1-3 Month T-Bill ETF, trades at $91.50, up 0.02% on the day, with a bearish technical signal from moving averages. The fund provides exposure to short-term U.S. Treasury bills, with recent institutional buying activity noted. Key support and resistance cluster around $91, while the relative strength index at 21.69 indicates potential oversold conditions.
The outlook for BIL is influenced by Federal Reserve policy expectations and Treasury yield movements. Rising yields may pressure returns, but the fund offers a low-risk cash alternative. Risks include interest rate volatility and inflation data surprises, with investor sentiment cautious amid geopolitical tensions affecting oil prices and bond markets.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
